What difference would an empagliflozin CVD indication make?
When a Food and Drug Administration advisory committee met on June 28 to consider a new indication for the type 2 diabetes drug empagliflozin – reduction of cardiovascular mortality in patients with...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Family Practices | Food and Drug Administration (FDA) | Heart | Jardiance | Primary Care